What is the Physician's Fiduciary Responsibility? The FDA Pulmonary and Allergy physic Advisory Committee recently approved the modern drug to treat cystic fibrosis.

What is the Physician's Fiduciary Responsibility?

The FDA Pulmonary and Allergy physic Advisory Committee recently approved the modern drug to treat cystic fibrosis, Pulmozyme (Genentech) a recombinant DNA-ase. Although formal approval is still pending, approval on the advisory committee is generally followed at approval from the FDA Commissioner, Dr David Kessler

The committee meeting is noteworthy for several reasons. First, the physic went from concept to advisory committee in 5 years, half the normal growth time. Furthermore, the advisory committee meeting came simply 4 months after Genetech's application was received. The expedited proces is part of Dr Kessler's laudable goal for the FDA to more quickly review mix with drugss for life-threatening ailments.

Also noteworthy was the members' discussion of the drug's efficacy v its price With regard to efficacy, earnestly of the committee's consideration was based primarily forward one unpublished study in cystic fibrosis patients.[1] Other preliminary data are available.[2,3] The considered studious mood was a large, 6-month placebo-controlled trial of once-and twice-daily administration of Pulmozyme The enthralls were "stable" outpatients with a lung capacity of at least 40 percent of normal. consequence criteria included documented respiratory tract infections as determined from the attending physician, pulmonary function standards (spirometry), and morbidity parameters (days of hospitalization, antibiotic therapy, and general well-being). Compared to placebo, those taking a once-daily dose of Pulmozyme from one side of to the other a 6-month period had a statistically significant decrease in respiratory infections, exhausted an average of 1.4 fewer hospital days, 27 fewer days forward an antibiotic regimen, and 15 fewer days dwelling from work or school. Spirometry improved solitary 5.8 percent, while mortality was unchanged.

Several disquieting aspects of this close attention regarding efficacy were also discussed. First, long-term patient benefit could not be ascertained befitting to the relatively short duration of the inquiry Second, 3 percent of patients receiving the once-daily dose and 5 percent of those receiving the twice-daily dose produc antibodies to the physic Third, concern was raised regarding the necessity of delivering this inhalation physic with a "dedicated" nebulizer. Fourth, when the eventuates were analyzed by age, those patients across 20 years of age appeared to obtain greater benefit from a twice-daily dose, although the consequence s were statistically inconclusive. Finally, an spread continuation of the controlled trial did not point out to continued statistical benefit in decreased respiratory tract infections for the once-a-day dose.

Regarding take away from the question of the drug's price was raised in the meeting. "How abundant will Genentech charge for Pulmozyme?" The answer has gigantic financial implications for a unsalable article that cost millions to unravel but which treats a patient population of solely 30,000 in the United States and 55000 worldwide. The patient population may be expanded as Genentech is reported to be also testing the physic in chronic bronchitis.

The answer given through Genentech was equivocal. They indicated the expense of the drug had not been place although it is widely reported that the company is considering charging about $10000 a year for the remedy In an unusual public statement during the committee meeting, Dr Kessler reminded the committee that its decision had reimbursement dependence of cause and effects At the end of 8 hours of discussion, the committee supported the approval of Pulmozyme in a once-daily dose.

In this day and age of fiscal restraints and ever-increasing healthcare sumptuousnesss physicians should address the issue of therapeutic efficacy v sumptuousness As a member of the advisory committee, I was businessed about approving a drug with limited efficacy however potentially huge costs that will be borne by dint of all of us. The question arises, "How earnestly is some efficacy worth?" The question is level more poignant when the relatively young age of cystic fibrosis patients and the life-threatening nature of their illness is considered.

I cannot allege a title to to have the answers. In the best of all worlds, physicians would be totally immune from the impact of finances upon therapeutic decisions. Now however, in the real world, we are not, nor showed we be immune from these decisions. Physicians have a fiduciary responsibility not merely to the patients for whom the of recent origin therapy is being considered, on the contrary also to other patients whose care will be diminished by way of the use of expensive therapy. Indeed, use of expensive modern therapy might also limit other therapies in the same patient population for whom the recently made known therapy is being considered (eg lung transplantation).

This is not an isolated case. Another example is thrombolytic therapy of acute myocardial infraction where the earnestly more expensive tissue plasminogen activator (tPA) was newly found to have a small however significant effect as compared to the often less expensive streptokinase therapy.[4] My belief is that prioritization of therapy based onward efficacy as well as in part at cost will have to take place. I doubt that any strange health care policy will entirely dislodge the need for this debate in which physicians should be included.

...